drugset
drugset / Trial / NCT06168786

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

NCT06168786 ↗

Phase 2 Recruiting 40 enrolled Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment

Summary

A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer

Timeline

Start
2023-06-20
Primary completion
2026-02-28
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg Intravenous
Subject Fruquintinib Small molecule 5 mg Oral

Indications

colorectal cancer